Daniel J. Lenihan
A5045593578- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Treatment and Pharmacology
- Heart Failure Treatment and Management
- Cardiac Imaging and Diagnostics
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiovascular Function and Risk Factors
- Peptidase Inhibition and Analysis
- Parathyroid Disorders and Treatments
- Cardiac tumors and thrombi
- Multiple Myeloma Research and Treatments
- Cardiac Structural Anomalies and Repair
- Cardiac pacing and defibrillation studies
- HER2/EGFR in Cancer Research
- Mechanical Circulatory Support Devices
- Chronic Myeloid Leukemia Treatments
- Cardiac electrophysiology and arrhythmias
- Protein Degradation and Inhibitors
- Acute Myocardial Infarction Research
- Renal cell carcinoma treatment
- Cancer-related cognitive impairment studies
- Transplantation: Methods and Outcomes
- Eosinophilic Disorders and Syndromes
- Cardiac Arrhythmias and Treatments
- Childhood Cancer Survivors' Quality of Life
- Atrial Fibrillation Management and Outcomes
Washington University in St. Louis
2005-2025
Saint Francis Medical Center
2022-2025
St. Francis Medical Center
2024
Government of the United States of America
2022
Jewish Hospital
2021
Barnes-Jewish Hospital
2020-2021
Vanderbilt University Medical Center
2012-2020
University of Pennsylvania
2016-2020
Marienkrankenhaus Hamburg
2020
Bristol-Myers Squibb (United States)
2020
2-D : two-dimensional 3-D : three-dimensional 5-FU : 5-fluorouracil ACE : angiotensin-converting enzyme ARB : angiotensin II receptor blocker ASE : American Society of Echocardiography BNP : B-type natriuretic peptide CABG : coronary artery bypass graft CAD :
65-74 years, Sex category (female) CIED Cardiac implantable electronic device CML Chronic myeloid leukaemia CMR magnetic resonance COMPASS-CAT Prospective COmparison of Methods for thromboembolic
Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies that can interfere with the efficacy treatment, decrease quality life, or impact actual survival patient cancer. The purpose this effort was to develop recommendations for prevention and monitoring cardiac in survivors adult-onset cancers. Methods Recommendations were developed by an expert panel multidisciplinary representation using systematic review (1996 2016) meta-analyses, randomized clinical...
Trastuzumab is an important biologic agent with significant activity in breast cancers that overexpress the HER2/neu marker. However, trastuzumab associated cardiotoxicity has not yet been fully explored. We present our experience patients who developed trastuzumab-related cardiotoxicity.Over a 4-year period, 38 HER2/neu-positive cancer were referred for suspected cardiotoxicity. All had previously received anthracycline-based chemotherapy. Results After doxorubicin but before trastuzumab,...
The discipline of Cardio-Oncology has seen tremendous growth over the past decade. It is devoted to cardiovascular (CV) care cancer patient, especially mitigation and management CV complications or toxicities therapies, which can have profound implications on prognosis. To that effect, many studies assessed in patients undergoing various types therapies; however, direct comparisons proven difficult due lack uniformity toxicity endpoints. Similarly, clinical practice, there be substantial...
Purpose To evaluate the cardiac safety of long-term trastuzumab therapy in patients with human epidermal growth receptor 2 (HER2) –overexpressing metastatic breast cancer (MBC) treated at The University Texas M.D. Anderson Cancer Center (Houston, TX). Patients and Methods Among 218 MBC trastuzumab-based for least 1 year, 173 were assessable toxicity. Cardiac events (CEs) defined as follows: asymptomatic decrease left ventricular ejection fraction (LVEF) below 50%; 20 percentage points LVEF...
Cardiovascular adverse events (CVAEs) can occur during proteasome inhibitor (PI) therapy. We conducted a prospective, observational, multi-institutional study to define risk factors and outcomes in patients with multiple myeloma (MM) receiving PIs.Patients relapsed MM initiating carfilzomib- or bortezomib-based therapy underwent baseline assessments repeated at regular intervals over 6 months, including cardiac biomarkers (troponin I T, brain natriuretic peptide [BNP], N-terminal proBNP),...
Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on long-term efficacy tafamidis from an ongoing extension (LTE) to pivotal ATTR-ACT (Tafamidis Transthyretin Cardiomyopathy Clinical Trial).Patients with cardiomyopathy who completed could enroll LTE, continuing same dose or, if previously treated placebo, randomized (2:1) meglumine 80 or 20 mg. All patients LTE transitioned free acid 61 mg (bioequivalent mg) following a...
Abstract BACKGROUND. Sunitinib malate is a novel multitargeted receptor tyrosine kinase inhibitor with established efficacy in the treatment of metastatic renal cell carcinoma and imatinib‐resistant gastrointestinal stromal tumor. This report describes development heart failure cancer patients who received this agent. METHODS. A retrospective study was conducted at M. D. Anderson Cancer Center during 1‐year period on sunitinib developed failure. RESULTS. During 2006, 6 224 (2.7%) (HF) that...